Department of Hematology, Myeloma Research Center of Beijing, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China.
Department of Hematology, Kailuan General Hospital, Tangshan, Hebei Province, China.
Cancer Epidemiol. 2022 Jun;78:102168. doi: 10.1016/j.canep.2022.102168. Epub 2022 Apr 29.
Previous retrospective studies showed that the incidence and mortality rates for MM in China were lower than those in western countries. A large-scale prospective study on incidence and mortality rates of MM is still lacking.
Based on the prospective Kailuan Cohort study in China, we included all patients with MM in Kailuan Cohort from June 1, 2008 to December 31, 2016. Using the numbers of diagnosed cases and deaths during the study period as the numerators and the corresponding observed person-years as the denominators respectively, we calculated crude incidence and mortality rates. The 95% confidence intervals for crude incidence rate and mortality rate were estimated base on Poisson distribution. Rates were standardized by direct standardization according to the China population in 2000 and Segi' world standard population.
A total of 22 members from Kailuan Cohort were first diagnosed with MM between 2008 and 2016. The calculated crude incidence rates were 2.8 (95% CI, 1.7-4.2) per 100,000 person-years for all participants. The standardized incidence rate was 0.9 per 100,000 person-years (95% CI, 0.5-2.1) when standardized by 2000 China population census data, and 1.0 per 100,000 person-years (95% CI, 0.6-1.8) when standardized by Segi's world standard population (WSP). The calculated crude mortality rates were 2.3 (95% CI, 1.4-3.6) per 100,000 person-years. The mortality standardized by 2000 China population census data was 0.7 per 100,000 person-years (95% CI, 0.3-1.9), and 0.9 per 100,000 population (95% CI, 0.5-1.7) when standardized by Segi's WSP. Both incidence and mortality for males were higher than that for females almost in all age groups. Both rates increased steadily with age.
In this community-based prospective cohort study, we found that the incidence of MM in China was far lower than that in American and Europe.
先前的回顾性研究表明，中国多发性骨髓瘤（MM）的发病率和死亡率低于西方国家。目前仍缺乏大规模的 MM 发病率和死亡率的前瞻性研究。
本研究基于中国的前瞻性开滦队列研究，纳入了 2008 年 6 月 1 日至 2016 年 12 月 31 日期间开滦队列中所有 MM 患者。以研究期间的诊断病例数和死亡人数为分子，相应的观察人年数为分母，分别计算粗发病率和死亡率。发病率的 95%置信区间基于泊松分布估计。发病率和死亡率分别按中国 2000 年人口和 Segi 世界标准人口进行直接标准化。
2008 年至 2016 年间，共有 22 名开滦队列成员首次被诊断为 MM。所有参与者的粗发病率为 2.8（95%CI，1.7-4.2）/10 万人年。按 2000 年中国人口普查数据标准化后，发病率标准化率为 0.9/10 万人年（95%CI，0.5-2.1），按 Segi 世界标准人口（WSP）标准化后为 1.0/10 万人年（95%CI，0.6-1.8）。粗死亡率为 2.3（95%CI，1.4-3.6）/10 万人年。按 2000 年中国人口普查数据标准化后，死亡率标准化率为 0.7/10 万人年（95%CI，0.3-1.9），按 Segi 世界标准人口（WSP）标准化后为 0.9/10 万人年（95%CI，0.5-1.7）。各年龄段男性的发病率和死亡率均高于女性，且随着年龄的增长而稳步上升。
在这项基于社区的前瞻性队列研究中，我们发现中国 MM 的发病率远低于美国和欧洲。
